

IN-SILICO ANALYSIS AND COMPUTER AIDED DRUG DESIGNING APPROACH FOR MUTANT CANCER GENE

UMA KUMARI¹, DEVENDRA KUMAR², NITIKA KUMARI³ & NIDHI AGARWAL⁴

¹Bioinformatics Scientist, Rapture Biotech International Pvt. Ltd, Noida-201301, India

²Trainee Rapture Biotech Noida, India

³Trainee Rapture Biotech Noida, India

⁴Assistant Professor D N college, Hisar, India

ABSTRACT

Identification and validation of the receptor and drug is the key stage in the drug discovery pipeline. The method of drug designing has been a difficult task that needs at the same time optimizing varied factors from increasing compound activity, affectivity to minimizing toxicity and adverse reactions. A drug could be a chemical substance that affects the processes of the mind or body that is employed in designation, treatment and interference of illness or different abnormally. Identification of the drug target molecule by using bioinformatics tool. In-silico “performed on pc or computational stimulation.” Lead identification- results of target validation assists in lead compound identification. Chemical compounds showing desired biological or pharmacologic activity- initiates development of recent clinical relevant compound. These compounds select diagnosis studies. Includes natural product, chemical libraries & machine healthful chemistry. Molecular docking will be performed to study the interaction of human p53 co-domain mutant gene and the associated ligand. In silica analysis and computer aided drug designing to access their potential anti-cancer activity to metabolic site of ligand. The analysis of prediction of conformation binding as well as the position and binding site within the binding affinity

KEYWORDS: Mutant cancer Gene, Molecular Docking, CADD, Binding Affinity & Ligand Fit

Received: Sep 14, 2021; **Accepted:** Oct 04, 2021; **Published:** Oct 21, 2021; **Paper Id.:** IJBTRDEC20214

INTRODUCTION

Information concerning the 3D shapes of proteins, nucleic acids, and sophisticated assemblies that facilitate students and researchers perceive all aspects of biological and agricultural, from super molecule synthesis to malady. As a member of the Protein databank, the database curate curates explanation of data information. The Protein Data base using method as software tools and resources for analysis and chemical drugs in 3D structural biology, process technique by applying identification code of protein. Retrieve structures by PDB ID. PyMOL is one in every of the few ASCII text file model visual image tools obtainable to be employed in structural biology. The PYMOL a district of the software’s name refers to the program having been written among the artificial language Python. PyMOL, is a molecular graphics tool, has been widely used for 3D visual images of proteins, nucleic acids, little molecules, negatron densities, surfaces. It's additionally capable of piece of writing molecules, ray tracing, and creating movies. PyMOL is a molecular graphics program which will be freely downloaded and put in on Windows or UNIX operating system. Cancer group of disease which shows the changes in normal cells within the body showing abnormal growth forming a lump called a tumour; this is often true of all cancers except leukemia (cancer of the blood). Untreated tumors can spread into the normal tissue, or to other parts of the body

via the bloodstream and lymphatic systems, and may affect the whole metabolism system and the other parts.

The analysis of mutant p53 downstream sample required acceptable in expression of gene lead in cell cycle arrest or to induction of caspase-mediated cell death. Different forms of gene over expression of p53 resulted in cell cycle where the genes that regulate cell cycle phase exceedingly in a dependent manner. (Kannan K, Amariglio N, Rechavi GSL. Ongusaha PP, Ouchi T, and Kim KSL.2000) the intensive analyses are done on the complete apoptotic pathway likewise that was mediated by p53. (Kannan K, Kaminski N, Rechavi GSL. Zhao R, Gish K, Murphy MSL. Wu Q, Kirschmeier P, Hockenberry TSL.2002)

Cell lines representing all major growth varieties were utilized to attempt to maximize at mutant p53 regulated genes altogether the growth varieties. Kannan et al, 2001, (Zhao R, Gish K, Murphy MSL.2000) the carcinoma cell line H1299 to investigate the p53 mediate transcriptional. The super molecule changes from a mutant to wild-type conformation in temperature shift from 37°C (non-permissive) to 32°C (permissive temperature) induces in cell cycle (Owen-Schaub avoirdupois unit, Zhang W, Cusack JC.1995)or apoptosis(Kannan K, Kaminski N, Rechavi GSL. Lotem J, Gal H, Hindu deity RSL2003) reckoning. The super molecule synthesis doesn't need, it allowed U.S.A. to tell apart the targets that are directly by exploitation the super molecule synthesis wherever the mutant p53 remained unchanged. (Zhao R, Gish K, Murphy MSL.2000)The alternative method was in cancer gene throughout inhibit of the p53 iatrogenic caspase-mediated cell death by cytokines and other factors. (Lotem J, Gal H, Kama RSL.2003) Same conformational was utilized in different cell varieties. (Li C, Shridhar K, Liu J. Mirza A, Wu Q, Wang LSL.2003)

Structure conformational switch in a different way, wild-type p53 over expressed was achieved by exploitation using recombinant agent, chemotherapeutical medicine them. Cells that lack wild sort p53 were infected with CMV promoter (Ad5CMV-p53) and ribonucleic acid was harvested at completely different time points. (Kimura T, Gotoh M, Nakamura YSL. Ueda K, Arakawa H, Nakamura Y.2003)On the opposite hand, studies that were geared toward characteristic the genes concerned in p53 mediate caspase-mediated cell death used chiefly chemotherapeutical agents a p53 activating the topoisomerase II matter,(Tan M, Wang Y, Guan KSL. Wang Y, Rea T, Bian JSL.19985) Doxorubicin(Robles AI, Bemmels NA, Foraker AB.2001) and Camptothecin, a polymer damaging agent that functions through p53-dependent mechanism.43 (Zhao et al, 2000), The actinic radiation and Gamma induce in p53 mutant gene expression and subsets of organic phenomenon involving in natural way in patterns specific to every mode of activation. (Kannan et al,) have utilized a muristerone inducer of inducible stimulate in transcriptional to over-express p53 and p21 encoded gene chromosome six (Yu J, Zhang L, Hwang PM, Rago C, Kinzler KW, Vogelstein B.1999) and metallothionein promoter was utilized by Zhao et al. The genetic variation and background the somatic mutation affect in pre-m RNA.




Figure 1: A Progress for Drug Discovery: from Target Identification to Drug Approval.

MATERIAL AND METHODS

Bioinformatics methods such as image and signal processing allow mining of useful outcomes from a large volume of raw data is one of the important aspects in experimenting molecular biology, in the field of genetics, it supports in explaining and sequencing genomes and their experimental mutations. It plays a significant part in the text breakdown of biological literature and the expansion of biological and gene ontologies to establish and request biological data. It also helps in the analysis of molecular modelling protein orientation and regulation. In the medicine and biological sciences, a wealth of information is provided by chemical database. Many individuals are familiar with PubMed and Medline Plus - searchable databases to the literature. Bioinformatics resources propaganda is to develop a new biological and chemical database to help in the understanding of fundamental ADME processes that can control disease and health by the metabolic processes. The PDB is single, worldwide safe deposit box for structural data of molecules of life. It is crucial for knowing critical areas of science including medicines, drug discovery, education, and fundamental biology for getting to know about the 3D structures of biological macromolecules. The PDB is significant in many of the areas of structural biology like structural genomics. It is now important for many funding agencies and major scientific journals to collect and give way their structures to the PDB. In the PDB there are many databases that use protein structures reposit in PDB. AutoDock is an Insilco process of docking technique. It is showing molecular visualization of small molecules, like key n lock technique. There are recent distributions of AutoDock that contains two generations of software's that are AutoDock4 and AutoDock Vina. PyMol is broadly used for 3D vision of macromolecules and it is a cross platform for molecular graphic tool. PyMol has been broadly magnified by many plugins that include homology analysis, protein-ligand docking, phamacophore modeling VS, and MD simulations. The RCSB PDB curates and explains PDB data as an associate of the wwPDB. By providing resources and tools for scientific method to discover the beneficial work in precision medicine. The mutation study in various cancer type topological parameters determine the number of mutations.

RESULT AND DISCUSSIONS

The Protein files which is showing every atom within the protein data to be utilized in a docking experiment. Preparing the data file involves ensuring that its atoms conform to the docking software by adding charges if necessary, adding polar hydrogen's in structure. Ligand preparation is compulsory in a flexible ligand-protein docking program which basically runs as step by step procedure: the grid map of interactions of the bounding site with some atom types in auto-grid and the analysis of the lligand respecting this map in drug designing software.

A whole PDBQT file must have:-partial charges, AutoDock have 4 atom-types. PyMol software is used to visualize the protein file in specific format, by converting the structural file format. The structure visualize by x-ray crystallography technique and, nuclear magnetic resonance Spectroscopy. The assistance of starting data, in 3D modeling use these processes or methodology to work out the situation of every atom present in every other during a molecule. The differences exist between completely in cancer sorts in terms of their genetic mutation heterogeneousness and, what is more, being evolution are often altered by exposure to chemotherapeutics [McGranahan, N., & Swanton, C. (2017) Gerlinger, M., & Swanton, C. (2010)]. Growth heterogeneousness isn't in the growth and may extend into the growth other environment in immune cells, epithelial tissue, and substitution matrix elements, which will propagation of a growth in cancerous and its response in medical treatment [Tammela, T., & Sage, J. (2020)]. The total graphical data of current one relating to the many different cancer cells. The cell culture of any tumor cells can model genomic variation and transcriptomic changes seen in primary tumors [Tammela, T., & Sage, J. (2020)].

In automated docking device approaches, planned to forecast how small molecules, like enzymes for the curable, binding of known structures. There are recent distributions of AutoDock that contains two generations of software's that are AutoDock4 and AutoDock Vina. PyMol is broadly used for 3D vision of macromolecules and it is a cross platform for molecular graphic tool.




Figure1: Grid Dimension of Molecular Docking in Ligand and Protein.




Figure 2: Analysis of Ligand.




Figure 3: Analysis of Protein and Ligand in PyMol (Hydrogen Bond between Protein and Ligand).

The computational models of CADD application in check the toxic compound for drug so understand that the medicine work in favor of precision medicine. The earlier molecules are Lead identification- results of target validation

assists in lead compound identification. Chemical compounds showing desired biological or pharmacologic activity-initiates development of recent clinical relevant compound. These compounds select diagnosis studies. Includes natural product, chemical libraries & machine healthful chemistry. Drug Designing helps in predicting the structure and functions of newly identified sequence DNA, RNA and protein used in drug designing for understanding chemical system in different ways shows the extensive impact in the area of drug designing.

CONCLUSIONS

The chemo informatics database growing as an explosion in currently used to find out the improved design of ligands and inhibitors with the desired specificity, will helpful also now and next generation with minimal side effects to people. Cancers comprise a group of diseases that enlargement of cell growth with the potential to invade or unfold to alternative elements. In the P53 sequence- this is often growth sequence suppressor cistronfactor } this is often conjointly referred to as TP53 gene and growth supermolecule p53 gene. As programs square measure developed by varied analysis teams, a standardized easy graphical operating setting combining process techniques like moorage, scoring, molecular dynamics simulations, and free energy calculations is required. The goal of this work was to produce a process platform that facilitates medicative chemists, many that aren't specialists in process methodologies, to utilize many common process techniques to drug discovery and aimed to initiate cooperative efforts among process researchers to mix alternative open supply process strategies underneath one, simply intelligible graphical programmed.

REFERENCES

1. Baker SJ, Fearon ER, Nigro JM. et al., Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas *Science* 1989;244:217–221. [PubMed]
2. Chen J., Lai L. (2006). Pocket v.2: Further developments on receptor-based pharmacophore modeling. *J. Chem. Inf. Model.* 46, 2684–2691. 10.1021/ci600246s [PubMed] [CrossRef] [Google Scholar]
3. Chen X., Yan C. C., Zhang X., Zhang X., Dai F., Yin J., et al. (2016). Drug-target interaction prediction: databases, web servers and computational models. *Briefings Bioinf.* 17, 696–712.
4. Consortium, I. T. P.-C. A. o. W. G. (2020). Pan-cancer analysis of whole genomes. *Nature*, 578(7793), 82–93. <https://doi.org/10.1038/s41586-020-1969-6>. CAS Article Google Scholar
5. Drews J. (2000). Drug discovery: a historical perspective. *Sci. (New York N.Y.)* 287, 1960–1964. 10.1126/science.287.5460.1960 [PubMed] [CrossRef] [Google Scholar]
6. Eliyahu D, Michalovitz D, Eliyahu SSL. et al. Wild-type p53 can inhibit oncogene-mediated focus formation. *Proc Natl Acad Sci.* 1989;86:8763–8767. [PMC free article] [PubMed]
7. Ferreira L. G., Dos Santos R. N., Oliva G., Andricopulo A. D. (2015). Molecular Docking and Structure-Based Drug Design Strategies. *Molecules* 20, 13384–13421. 10.3390/molecules20071338
8. Finlay CA, Hinds PW, Levine AJ. The p53 proto-oncogene can act as a suppressor of transformation. *Cell.* 1989;57:1083–1093.
9. Fortin A, Cregan SP, MacLaurin JG. et al. APAF1 is a key transcriptional target for p53 in the regulation of neuronal cell death. *J Cell Biol.* 2001;155:207–216. [PMC free article] [PubMed]
10. Gerlinger, M., & Swanton, C. (2010). How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. *British Journal of Cancer*, 103(8), 1139–

1143. <https://doi.org/10.1038/sj.bjc.6605912>. CAS Article PubMed PubMed Central Google Scholar
11. Gerlinger, M., Rowan, A. J., Horswell, S., Math, M., Larkin, J., Endesfelder, D., et al. (2012). Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. *The New England Journal of Medicine*, 366(10), 883–892. <https://doi.org/10.1056/NEJMoa1113205>. CAS Article PubMed PubMed Central Google Scholar
 12. Gerstung, M., Jolly, C., Leshchiner, I., Dentre, S. C., Gonzalez, S., Rosebrock, D., et al. (2020). The evolutionary history of 2,658 cancers. *Nature*, 578(7793), 122–128. <https://doi.org/10.1038/s41586-019-1907-7>. CAS Article PubMed PubMed Central Google Scholar
 13. Ghofrani H. A., Osterloh I. H., Grimminger F. (2006). Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. *Nat. Rev. Drug Discovery* 5, 689–702. 10.1038/nrd2030 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
 14. Halperin I, Ma B., Wolfson H., Nussinov R. (2002). Principles of docking: An overview of search algorithms and a guide to scoring functions. *Proteins* 47, 409–443. 10.1002/prot.10115 [PubMed] [CrossRef] [Google Scholar]
 15. Hinohara, K., & Polyak, K. (2019). Intratumoral heterogeneity: more than just mutations. *Trends in Cell Biology*, 29(7), 569–579. <https://doi.org/10.1016/j.tcb.2019.03.003>.
 16. Hopkins A. L. (2008). Network pharmacology: the next paradigm in drug discovery. *Nat. Chem. Biol.* 4, 682–690. 10.1038/nchembio.118
 17. Janiszewska, M., Tabassum, D. P., Castano, Z., Cristea, S., Yamamoto, K. N., Kingston, N. L., et al. (2019). Subclonal cooperation drives metastasis by modulating local and systemic immune microenvironments. *Nature Cell Biology*, 21(7), 879–888. <https://doi.org/10.1038/s41556-019-0346-x>. CAS Article PubMed PubMed Central Google Scholar
 18. Kannan K, Amariglio N, Rechavi GSL et al. DNA microarrays identification of primary and secondary target genes regulated by p53. *Oncogene*. 2001; 20:2225–2234. [PubMed]
 19. Kannan K, Amariglio N, Rechavi GSL et al. Profile of gene expression regulated by induced p53: connection to the TGF- β family. *FEBS Lett*. 2000; 470:77–82. [PubMed]
 20. Kannan K, Kaminski N, Rechavi GSL et al. DNA microarray analysis of genes involved in p53 mediated apoptosis activation of *apaf-1*. *Oncogene*. 2001; 20:3449–3455. [PubMed]
 21. Kimura T, Gotoh M, Nakamura YSL et al. *hCDC4b*, a regulator of cyclin E, as a direct transcriptional target of p53. *Cancer Sci*. 2003; 94:431–436. [PubMed]
 22. Knudson AG. Two genetic hits (more or less) to cancer. *Nat Rev Cancer*. 2001;1: 157–162. [PubMed]
 23. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. *Proc Natl Acad Sci USA*. 1971;68:820–823. [PMC free article] [PubMed]
 24. Kortagere S., Ekins S. (2010). Troubleshooting computational methods in drug discovery. *J. Pharmacol. Toxicol. Methods* 61, 67–75. 10.1016/j.vascn.2010.02.005
 25. Lazo J. S., Sharlow E. R. (2016). Drugging Undruggable Molecular Cancer Targets.. *Annu. Rev. Phar. Toxicol.* 56, 23–40. 10.1146/annurev-pharmtox-010715-103440 [PubMed] [CrossRef] [Google Scholar]
 26. Li C, Shridhar K, Liu J. Molecular characterization of oncostatin M-induced growth arrest of MCF-7 cells expressing a temperature sensitive mutant of p53. *Breast Cancer Res Treat*. 2003;80:23–37. [PubMed]
 27. Lotem J, Gal H, Kama RSL et al. Inhibition of p53-induced apoptosis without affecting expression of p53 regulated

- genes. *Proc Natl Acad Sci USA*. 2003; 100:6718–6723. [PMC free article] [PubMed]
28. Maley, C. C., Aktipis, A., Graham, T. A., Sottoriva, A., Boddy, A. M., Janiszewska, M., et al. (2017). Classifying the evolutionary and ecological features of neoplasms. *Nature Reviews. Cancer*, 17(10), 605–619. <https://doi.org/10.1038/nrc.2017.69>.CAS
 29. Mathi P., Prasad M. V., Botlagunta M., Ravi M., Ramachandran D. (2018). De novo design of selective Sortase-A inhibitors: Synthesis, structural and in vitro characterization. *Chem. Data Collect.* 15, 126–133. 10.1016/j.cdc.2018.04.007 [
 30. Maxwell SA, Davis GE. Biological and molecular characterization of an ECV-304-derived cell line resistant to p53 mediated apoptosis. *Apoptosis*. 2000; 5:277–290. [
 31. Maxwell SA, Davis GE. Differential gene expression in p53-mediated apoptosis-resistant vs. apoptosis-sensitive tumor cell lines. *Proc Natl Acad Sci USA*. 2000;97: 13009–13014.
 32. Goswami, Anurupa, and DK SHARMA. "Emerging Players in Aging Process: A Review." *International Journal of Applied and Natural Sciences (IJANS)* 6.4: 23-36.
 33. Montano-Soto, Tatiana, et al. "Genotoxic biomonitoring and exposure to pesticides in women laborers at manadero valley in Baja California, Mexico." *International Journal of Applied and Natural Sciences* 3.2 (2014): 89-96.
 34. Devi, Meena. "Synthesis and characterization of palladium nanoparticles & its contribution in photothermal therapy of cancer." *International Journal of General Medicine and Pharmacy (IJGMP)* 8.5: 11-18.
 35. Chander, Mukesh. "A Comparative Study of Bioactive Molecules in Treatment and Control of Cancer." *International Journal of Mechanical and Production Engineering Research and Development (IJMPERD)* 10 (2020): 10499-10514.
 36. Ramakrishnan, Ranjani. "Anticancer properties of blue green algae *Spirulina platensis*—A review." *International Journal of Medical and Pharmaceutical Sciences* 3 (2013): 159-168.

